Novartis breast cancer therapy gets FDA breakthrough designation
ZURICH (Reuters) - Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Health | Switzerland Health